Cancer
01 Jan 2013
Chemoradiotherapy in Patients with Localised Lung Cancer
The study compares 2 different methods of combined chemotherapy and radiotherapy for the treatment of localised lung cancer in patients not suitable for surgery. Hypothesis(es) to be tested: 1) Vinorelbine + cisplatin + high-dose palliative radiotherapy is superior to gemcitabine + high dose palliative radiotherapy in terms of efficacy…
Heart
01 Jan 2013
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II. Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability…
Children's health
01 Jan 2013
Early Antipseudomonal Therapy in Cystic Fibrosis
To determine a safe, effective, and systematic approach to antibiotic treatment of Pseudomonas infection in young children with cystic fibrosis. Official Title Conditions – Cystic Fibrosis- Infection- Lung Diseases Study Type Interventional Study Design Prevention, Randomized Further Details BACKGROUND: Cystic fibrosis (CF), an autosomal recessive disorder without a cure,…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel. Official Title A Phase 2 Efficacy and Safety Study of SU011248 in Patients with Metastatic Non-Small Cell Lung…
Lungs
01 Jan 2013
FLASH Study: A study of roflumilast versus placebo in patients with asthma
The purpose of this study is to determine whether roflumilast is effective in the treatment of asthma. Official Title FLASH Study: A 24 week randomized, controlled study of roflumilast versus placebo in patients with asthma Conditions Asthma Study Type Interventional Study Design Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy…
Cancer
01 Jan 2013
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a…
Infections
01 Jan 2013
Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus
Linezolid is the first of a new class of antibiotics with a unique mechanism of action against Methicillin-Resistant Staphylococcus Aureus (MRSA). This is a Phase IV, double-blinded, randomized study for patients with hospital acquired pneumonia proven to be caused by MRSA. Patients will be treated with linezolid or vancomycin for…
Blood
01 Jan 2013
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes…
Lungs
01 Jan 2013
Safety and Efficacy Study of CEP-10953 in the Treatment of Excessive Sleepiness Associated with Narcolepsy
The primary objective of this study is to determine whether treatment with CEP-10953 is more effective than placebo treatment for patients with excessive sleepiness associated with narcolepsy by measuring mean sleep latency from the Maintenance of Wakefulness (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500) and…
